Cargando…
Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3
Autores principales: | Zeyn, Yanira, Hausmann, Kristin, Halilovic, Melisa, Beyer, Mandy, Ibrahim, Hany S., Brenner, Walburgis, Mahboobi, Siavosh, Bros, Matthias, Sippl, Wolfgang, Krämer, Oliver H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624624/ https://www.ncbi.nlm.nih.gov/pubmed/37735559 http://dx.doi.org/10.1038/s41375-023-02036-2 |
Ejemplares similares
-
Inhibitors of class I HDACs and of FLT3 combine synergistically against leukemia cells with mutant FLT3
por: Wachholz, Vanessa, et al.
Publicado: (2021) -
Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition
por: Pons, Miriam, et al.
Publicado: (2021) -
Synthesis, Molecular Docking and Biological Characterization of Pyrazine Linked 2-Aminobenzamides as New Class I Selective Histone Deacetylase (HDAC) Inhibitors with Anti-Leukemic Activity
por: Ibrahim, Hany S., et al.
Publicado: (2021) -
Targeting the MYC interaction network in B-cell lymphoma via histone deacetylase 6 inhibition
por: Winkler, René, et al.
Publicado: (2022) -
Inhibitors of the Actin-Bundling Protein Fascin-1 Developed for Tumor Therapy Attenuate the T-Cell Stimulatory Properties of Dendritic Cells
por: Zeyn, Yanira, et al.
Publicado: (2022)